SG11201505928YA - 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors - Google Patents
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitorsInfo
- Publication number
- SG11201505928YA SG11201505928YA SG11201505928YA SG11201505928YA SG11201505928YA SG 11201505928Y A SG11201505928Y A SG 11201505928YA SG 11201505928Y A SG11201505928Y A SG 11201505928YA SG 11201505928Y A SG11201505928Y A SG 11201505928YA SG 11201505928Y A SG11201505928Y A SG 11201505928YA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphoinositide
- quinazolin
- pyrazolo
- pyrimidin
- hydroxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13275070 | 2013-03-15 | ||
EP13193372 | 2013-11-18 | ||
PCT/GB2014/050770 WO2014140597A1 (fr) | 2013-03-15 | 2014-03-14 | Dérivés de 2-((4-amino-3-(3-fluoro-5-hydroxyphényl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)méthyl)-3-(2-(trifluorométhyl)benzyl)quinazolin-4(3h)-one et leur utilisation comme inhibiteurs de la phosphoinositide 3-kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201505928YA true SG11201505928YA (en) | 2015-09-29 |
Family
ID=50349644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505928YA SG11201505928YA (en) | 2013-03-15 | 2014-03-14 | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
US (2) | US9745306B2 (fr) |
EP (1) | EP2970293B1 (fr) |
JP (1) | JP6353856B2 (fr) |
KR (1) | KR20150127607A (fr) |
CN (1) | CN105229007B (fr) |
AU (1) | AU2014229768B2 (fr) |
BR (1) | BR112015019754A8 (fr) |
CA (1) | CA2899812A1 (fr) |
CL (1) | CL2015002606A1 (fr) |
EA (1) | EA029218B1 (fr) |
ES (1) | ES2640624T3 (fr) |
GT (1) | GT201500218A (fr) |
HK (1) | HK1214591A1 (fr) |
IL (1) | IL240061A0 (fr) |
JO (1) | JO3279B1 (fr) |
MX (1) | MX2015012091A (fr) |
NI (1) | NI201500134A (fr) |
PE (1) | PE20151653A1 (fr) |
PH (1) | PH12015501836A1 (fr) |
SG (1) | SG11201505928YA (fr) |
TW (1) | TW201522341A (fr) |
UA (1) | UA116002C2 (fr) |
UY (1) | UY35446A (fr) |
WO (1) | WO2014140597A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198279B2 (en) | 2007-12-19 | 2012-06-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use |
PL2531502T3 (pl) | 2010-02-01 | 2014-08-29 | Cancer Research Tech Ltd | 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii |
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
AR094664A1 (es) | 2013-01-15 | 2015-08-19 | Incyte Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
CR20160600A (es) | 2014-07-04 | 2017-03-07 | Lupin Ltd | Quinolizione derivados como inhibidores pi3k |
WO2016010897A1 (fr) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016196244A1 (fr) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Composés de pyridineamine utiles en tant qu'inhibiteurs de kinase pim |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2019113487A1 (fr) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140938B1 (fr) | 1999-01-11 | 2003-08-27 | Princeton University | Inhibiteurs de haute affinite pour la validation de cibles, et leurs utilisations |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
ES2360933T3 (es) | 2000-04-27 | 2011-06-10 | Astellas Pharma Inc. | Derivados de heteroarilo condensados. |
EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
WO2003006628A2 (fr) | 2001-07-13 | 2003-01-23 | Virtual Drug Development, Inc. | Inhibiteurs de nad synthetase, et utilisations correspondantes |
WO2003007955A2 (fr) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Nouvelle utilisation |
AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
EP1661879A4 (fr) | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | Compose d'ether de diphenyle, sa methode de preparation et d'utilisation |
WO2005016349A1 (fr) | 2003-08-14 | 2005-02-24 | Icos Corporation | Methodes d'inhibition de l'accumulation des leucocytes |
WO2005016348A1 (fr) | 2003-08-14 | 2005-02-24 | Icos Corporation | Methodes d'inhibition de reponses immunes stimulees par un facteur endogene |
US20050239809A1 (en) | 2004-01-08 | 2005-10-27 | Watts Stephanie W | Methods for treating and preventing hypertension and hypertension-related disorders |
LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
EP1750714A1 (fr) | 2004-05-13 | 2007-02-14 | Vanderbilt University | Inhibiteurs selectifs de la phosphoinositide-3-kinase delta pour inhiber l'angiogenese |
CA2567883A1 (fr) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methodes de traitement et/ou de prevention de la proliferation aberrante des cellules hematopoietiques |
CA2569406A1 (fr) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methodes de traitement de troubles des mastocytes |
NZ553696A (en) | 2004-09-13 | 2010-02-26 | Ono Pharmaceutical Co | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
US20080287469A1 (en) | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
US20070063319A1 (en) | 2005-09-19 | 2007-03-22 | Bohumil Lojek | Film stack and method for fabricating the same |
CN101448505A (zh) * | 2006-04-04 | 2009-06-03 | 加利福尼亚大学董事会 | Pi3激酶拮抗剂 |
KR101499783B1 (ko) | 2006-04-04 | 2015-03-09 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
AR061664A1 (es) | 2006-06-29 | 2008-09-10 | Schering Corp | Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas. |
CA2668744C (fr) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Composes et procedes pour traiter des troubles de repliement de proteine |
WO2008067219A2 (fr) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Modulateurs quinazolinones de tgr5 |
WO2008104077A1 (fr) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt) |
WO2008140750A1 (fr) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Composés modulant la fonction du trp v3 |
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
WO2010036380A1 (fr) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Inhibiteurs hétérocycliques de kinases |
US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
EP2365810A2 (fr) | 2008-12-04 | 2011-09-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Médicaments à ciblage phosphatidylinositol-3-kinase p110 delta dans le traitement des troubles du snc |
US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
EP2411391A1 (fr) | 2009-03-24 | 2012-02-01 | Gilead Calistoga LLC | Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation |
RU2012104214A (ru) | 2009-08-05 | 2013-09-10 | Верситек Лимитед | Противовирусные соединения и способы их получения и применения |
GB0918249D0 (en) * | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
SI2834244T1 (sl) | 2012-03-13 | 2016-12-30 | Respivert Limited | Inhibitorji kristalinične PI3 kinaze |
AR095353A1 (es) * | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
-
2014
- 2014-03-13 JO JOP/2014/0103A patent/JO3279B1/ar active
- 2014-03-13 TW TW103108912A patent/TW201522341A/zh unknown
- 2014-03-14 JP JP2015562319A patent/JP6353856B2/ja not_active Expired - Fee Related
- 2014-03-14 MX MX2015012091A patent/MX2015012091A/es unknown
- 2014-03-14 UA UAA201507682A patent/UA116002C2/uk unknown
- 2014-03-14 PE PE2015001926A patent/PE20151653A1/es not_active Application Discontinuation
- 2014-03-14 CA CA2899812A patent/CA2899812A1/fr not_active Abandoned
- 2014-03-14 EA EA201591804A patent/EA029218B1/ru not_active IP Right Cessation
- 2014-03-14 AU AU2014229768A patent/AU2014229768B2/en not_active Ceased
- 2014-03-14 ES ES14712334.3T patent/ES2640624T3/es active Active
- 2014-03-14 CN CN201480015955.2A patent/CN105229007B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP14712334.3A patent/EP2970293B1/fr active Active
- 2014-03-14 BR BR112015019754A patent/BR112015019754A8/pt not_active IP Right Cessation
- 2014-03-14 UY UY0001035446A patent/UY35446A/es unknown
- 2014-03-14 WO PCT/GB2014/050770 patent/WO2014140597A1/fr active Application Filing
- 2014-03-14 KR KR1020157023823A patent/KR20150127607A/ko not_active Application Discontinuation
- 2014-03-14 US US14/777,021 patent/US9745306B2/en not_active Expired - Fee Related
- 2014-03-14 SG SG11201505928YA patent/SG11201505928YA/en unknown
-
2015
- 2015-07-21 IL IL240061A patent/IL240061A0/en unknown
- 2015-08-04 GT GT201500218A patent/GT201500218A/es unknown
- 2015-08-20 PH PH12015501836A patent/PH12015501836A1/en unknown
- 2015-09-11 CL CL2015002606A patent/CL2015002606A1/es unknown
- 2015-09-11 NI NI201500134A patent/NI201500134A/es unknown
-
2016
- 2016-03-03 HK HK16102451.0A patent/HK1214591A1/zh not_active IP Right Cessation
-
2017
- 2017-07-27 US US15/661,279 patent/US20170334919A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UA116002C2 (uk) | 2018-01-25 |
JO3279B1 (ar) | 2018-09-16 |
CN105229007A (zh) | 2016-01-06 |
CL2015002606A1 (es) | 2016-03-04 |
US20160039826A1 (en) | 2016-02-11 |
TW201522341A (zh) | 2015-06-16 |
UY35446A (es) | 2014-09-30 |
IL240061A0 (en) | 2015-09-24 |
EP2970293B1 (fr) | 2017-06-14 |
MX2015012091A (es) | 2016-04-15 |
EA029218B1 (ru) | 2018-02-28 |
EP2970293A1 (fr) | 2016-01-20 |
PE20151653A1 (es) | 2015-11-12 |
ES2640624T3 (es) | 2017-11-03 |
WO2014140597A1 (fr) | 2014-09-18 |
AU2014229768B2 (en) | 2018-01-04 |
HK1214591A1 (zh) | 2016-07-29 |
BR112015019754A2 (pt) | 2017-07-18 |
US20170334919A1 (en) | 2017-11-23 |
GT201500218A (es) | 2017-09-21 |
EA201591804A1 (ru) | 2016-01-29 |
JP2016510802A (ja) | 2016-04-11 |
NI201500134A (es) | 2016-01-06 |
BR112015019754A8 (pt) | 2019-11-12 |
CA2899812A1 (fr) | 2014-09-18 |
AU2014229768A1 (en) | 2015-08-06 |
JP6353856B2 (ja) | 2018-07-04 |
US9745306B2 (en) | 2017-08-29 |
CN105229007B (zh) | 2017-08-25 |
PH12015501836A1 (en) | 2015-11-09 |
KR20150127607A (ko) | 2015-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL240061A0 (en) | History of 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-h1-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl ) quinazoline-4(h3)-one and their use as phosphoinositide 3-kinase inhibitors | |
IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
IL264402B (en) | History of pyrrolo(2,3–d)pyrimidine for the treatment of viral infections and other diseases | |
EP3172214A4 (fr) | 2-amino-pyrido [2,3-d]pyrimidin -7 (8h)-one utilisés en tant qu'inhibiteurs de cdk et utilisations de ceux-ci | |
IL237761B (en) | History of pyrrolo[2,3–d]pyrimidine for the treatment of viral infections and other diseases | |
BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
IL255488B (en) | Pyrido[4,3-di]pyrimidine derivative and its pharmaceutically acceptable salt | |
HK1219277A1 (zh) | 新的***並 嘧啶衍生物 | |
IL227526A0 (en) | Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors | |
HRP20180788T1 (hr) | [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti | |
TWI799399B (zh) | 吡啶并〔3,4-d〕嘧啶衍生物及其藥學上所容許之鹽 | |
MA46937A (fr) | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
PT2729471E (pt) | Derivados do ácido carboxílico com um anel de oxazolo[5,4-d pirimidina | |
PT3842436T (pt) | Composições farmacêuticas compreendendo derivados de imidazopirimidina e imidazotriazina para utilização no tratamento de esquizofrenia | |
ZA201808361B (en) | Benzoxazine or quinazoline derivatives for use in the treatment of alzheimer¿s disease | |
TH1501005522A (th) | อนุพันธ์ 2-((4-อะมิโน-3-(3-ฟลูออโร-5-ไฮดรอกซีเฟนิล)-1h-ไพราโซโล[3,4-d]ไพริมิดีน-1-อิล)เมทธิล)-3-(2-ไตรฟลูออโรเมทธิล)เบนซิล)ควินาโซลิน-4(3h)-โอน และการใช้สารเหล่านี้เป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3- ไคเนส | |
HK1192237A1 (en) | Carboxylic acid derivatives with an oxazolo[5,4-d]pyrimidine ring [54-d] | |
IL253427A0 (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
TH1501007226A (th) | สารประกอบ 6,7-ไดไฮโดรไพราโซโล[1,5-a]ไพราซีน-4(5H)-โอน และการใช้ของ สิ่งนั้นในฐานะเป็นสารยับยั้งแอลโลสเตอริกของ mGluR2 รีเซ็ปเตอร์ |